Rahman A K M Rezaur, Babu Mahathe Hasan, Ovi Mustofa Khalid, Zilani Md Mahiuddin, Eithu Israt Sultana, Chakraborty Amit
Department of Physics, University of Chittagong, Chittagong, Bangladesh.
J Med Phys. 2024 Apr-Jun;49(2):137-147. doi: 10.4103/jmp.jmp_22_24. Epub 2024 Jun 25.
The utilization of actinium-225 (Ac) radionuclides in targeted alpha therapy for cancer was initially outlined in 1993. Over the past two decades, substantial research has been conducted, encompassing the establishment of Ac production methods, various preclinical investigations, and several clinical studies. Currently, there is a growing number of compounds labeled with Ac that are being developed and tested in clinical trials. In response to the increasing demand for this nuclide, production facilities are either being built or have already been established. This article offers a concise summary of the present state of clinical advancements in compounds labeled with Ac. It outlines various processes involved in the production and purification of Ac to cater to the growing demand for this radionuclide. The article examines the merits and drawbacks of different procedures, delves into preclinical trials, and discusses ongoing clinical trials.
1993年首次概述了锕-225（Ac）放射性核素在癌症靶向α治疗中的应用。在过去二十年中，已经进行了大量研究，包括Ac生产方法的建立、各种临床前研究以及多项临床研究。目前，越来越多标记有Ac的化合物正在临床试验中开发和测试。为了满足对这种核素日益增长的需求，正在建造或已经建立了生产设施。本文简要总结了标记有Ac的化合物的临床进展现状。它概述了Ac生产和纯化所涉及的各种过程，以满足对这种放射性核素不断增长的需求。本文研究了不同程序的优缺点，深入探讨了临床前试验，并讨论了正在进行的临床试验。
